TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4046122

Group type: EXPERIMENTAL
Intervention: Total WBC count
Number of subjects: 6222

Group type: EXPERIMENTAL
Intervention: Change in WBC count from baseline to annual examination
Number of subjects: 6222

Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 6222
Study: 30140328

Group type: EXPERIMENTAL
Intervention: Modified Brief Pain Inventory worst pain severity (m-BPI-WPS)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Change (PGIC)
Number of subjects: 452
Study: 27346176

Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Number of subjects: 71683

Group type: EXPERIMENTAL
Intervention: Low dose edoxaban
Number of subjects: 71683

Group type: EXPERIMENTAL
Intervention: High dose edoxaban
Number of subjects: 71683

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 71683
Study: 24618935

Group type: EXPERIMENTAL
Intervention: Empiric antibiotic therapy in FN episodes with bacteremia
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Patients with MDI
Number of subjects: 441
Study: 22142823

Group type: EXPERIMENTAL
Intervention: High T(ccr7) tumor infiltration
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High T(ccr7) and T(reg) tumor infiltration
Number of subjects: 76
Study: 20549832

Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/d
Number of subjects: 416

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 416
Study: 17490788

Group type: EXPERIMENTAL
Intervention: Accelerated diagnostic protocol
Number of subjects: 149
Study: 16206600

Group type: EXPERIMENTAL
Intervention: Enalapril + trimetazidine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Enalapril + placebo
Number of subjects: 64
Study: 12410482

Group type: EXPERIMENTAL
Intervention: Switching from protease inhibitors to alternative drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching thymidine analogue reverse-transcriptase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substitution of other agents for protease inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10190874

Group type: EXPERIMENTAL
Intervention: Testosterone (2.5 mg IV in 5 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7571745

Group type: EXPERIMENTAL
Intervention: Participation in structured quality circles
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group without peer review
Number of subjects: 25
Study: 2376378

Group type: EXPERIMENTAL
Intervention: Daunomycin applied to the vitreous cavity during pars plana vitrectomy (PPV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group treated with PPV and silicone tamponade alone
Number of subjects: 14
Study: 7317666

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure (207 micrograms/m3)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unpolluted air exposure
Number of subjects: 7
Study: 30168611

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) mediated by methylene blue and red laser diode (Periowave®, λ = 670 nm, 200 mW)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) based on 10 pulses/cm2 (Dye-VL-F module, Alma Lasers, λ = 500-600 nm, 10 J)
Number of subjects: 40
Study: 27839954

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 198
Study: 26101179

Group type: EXPERIMENTAL
Intervention: Nonrigid, inelastic lumbar brace (worn for 2 weeks)
Number of subjects: 54
Study: 25147253

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5121
Study: 21115098

Group type: EXPERIMENTAL
Intervention: Sandblasting with aluminium oxide particles followed by silane coupling agent
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immersion in 9.6% hydrofluoric acid gel for 60 s and silanization for 60 s
Number of subjects: 30

Group type: COMPARATOR
Intervention: No surface treatment (Control)
Number of subjects: 30
Study: 19814804

Group type: EXPERIMENTAL
Intervention: EPHX2 K55R polymorphism in CHD patients after PCI
Number of subjects: 706

Group type: COMPARATOR
Intervention: Control group (patients without CHD)
Number of subjects: 706
Study: 18046883

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 332510280

Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers (CCBs)
Number of subjects: 332510280

Group type: EXPERIMENTAL
Intervention: Alpha-1-blockers (A1Bs)
Number of subjects: 332510280

Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists (A2Ags)
Number of subjects: 332510280
Study: 14738560

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b plus Thymosin-alpha 1 (900 microg/m2 body surface area)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Interferon-alpha 2b alone
Number of subjects: 41
Study: 11601508

Group type: EXPERIMENTAL
Intervention: Intravenous 10% dextran 40
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 9240678

Group type: EXPERIMENTAL
Intervention: Wallstent with periprocedural heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wallstent without periprocedural heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Palmaz stent with periprocedural heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Palmaz stent without periprocedural heparin
Number of subjects: 24
Study: 8250191

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 50
Study: 2955033

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl oestradiol daily (OC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 0
Study: 30357434

Group type: EXPERIMENTAL
Intervention: Psychedelic truffles (microdose)
Number of subjects: 0
Study: 27474356

Group type: EXPERIMENTAL
Intervention: Prasugrel (2-30 mg single administration)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prasugrel (2.5-10 mg multiple administration)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prasugrel (up to 30 mg single administration and up to 10 mg maintenance dose)
Number of subjects: 90
Study: 24456422

Group type: EXPERIMENTAL
Intervention: L-PGDS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OPG
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OPN
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PAPP-A
Number of subjects: 120
Study: 22470524

Group type: EXPERIMENTAL
Intervention: Motor sequence learning task (MST) performance in patients with obstructive sleep apnea
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Motor sequence learning task (MST) plateau performance in patients with obstructive sleep apnea
Number of subjects: 31
Study: 21054614

Group type: EXPERIMENTAL
Intervention: Peer-based, personal risk network-focused HIV prevention intervention
Number of subjects: 227
Study: 18350391

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (six 20-minute sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-exercise control condition
Number of subjects: 24
Study: 16310197

Group type: EXPERIMENTAL
Intervention: Red wine (300 ml for 15 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: White wine (300 ml for 15 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no alcohol for 15 days)
Number of subjects: 20
Study: 12794960

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 0
Study: 10762178

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg x kg(‐1) over 1 h, followed by 5.4 mg x kg(‐1) x h(‐1) for 23 h)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nimodipine (0.015 mg x kg(‐1) x h(‐1) for 2 h followed by 0.03 mg x kg(‐1)h(‐1) for 7 days)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both Methylprednisolone and Nimodipine
Number of subjects: 106

Group type: COMPARATOR
Intervention: No medical treatment (Control group)
Number of subjects: 106
Study: 8819541

Group type: EXPERIMENTAL
Intervention: Milk-free diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unrestricted diet (atopic group)
Number of subjects: 22
Study: 1483668

Group type: EXPERIMENTAL
Intervention: Neomycin sulfate (6 g per os)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neomycin sulfate
Number of subjects: 39
Study: 3872075

Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Visual stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined vestibular and visual stimulation
Number of subjects: 30
Study: 29363339

Group type: EXPERIMENTAL
Intervention: Nurse-led, stage-matched intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 0
Study: 29126314

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard single-agent therapy
Number of subjects: 0
Study: 27154847

Group type: EXPERIMENTAL
Intervention: Filgrastim-stimulated marrow (G-BM)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Filgrastim-mobilized peripheral blood (G-PB)
Number of subjects: 230
Study: 24085401

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids-related metabolites
Number of subjects: 73
Study: 23241329

Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 21056464

Group type: EXPERIMENTAL
Intervention: Rivastigmine (1.5 mg twice daily increasing to 6 mg twice daily) as an adjunct to usual care with haloperidol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo as an adjunct to usual care with haloperidol
Number of subjects: 104
Study: 17785930

Group type: EXPERIMENTAL
Intervention: Efonidipine 20‐60 mg twice daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amlodipine 2.5‐7.5 mg once daily
Number of subjects: 21
Study: 15180833

Group type: EXPERIMENTAL
Intervention: Panoptic direct ophthalmoscope (PO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional direct ophthalmoscope (CO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both CO and PO
Number of subjects: 10
Study: 11178767

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel and clips
Number of subjects: 18

Group type: COMPARATOR
Intervention: Monopolar electrosurgery and clips
Number of subjects: 18
Study: 9710029

Group type: EXPERIMENTAL
Intervention: RBD group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-RBD group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients with prior SRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: RBD association with SRI
Number of subjects: 61
Study: 7526676

Group type: EXPERIMENTAL
Intervention: Celiprolol (selective beta blocker) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (not treated with celiprolol)
Number of subjects: 0
Study: 2690287

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study: 238256

Group type: EXPERIMENTAL
Intervention: Chlorazepate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31822745

Group type: EXPERIMENTAL
Intervention: Young adolescents with macrotrauma (T1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Older adolescents with macrotrauma (T1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Young adolescents without macrotrauma (T0)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Older adolescents without macrotrauma (T0)
Number of subjects: 70
Study: 27114243

Group type: EXPERIMENTAL
Intervention: Simulation-based training on the management of acute agitation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Didactic-based instruction (control)
Number of subjects: 26
Study: 25484317

Group type: EXPERIMENTAL
Intervention: Resistance exercise (EX)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Relaxation control (RC)
Number of subjects: 101
Study: 23339639

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) for a median of 3 days (IQR 2 to 8)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Control ventilation strategy targeting lung recruitment with low tidal volumes and high positive end-expiratory pressure
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: HFOV group
Number of subjects: 548
Study: 21751904

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus short-term ADT (4 months of total androgen suppression starting 2 months before radiotherapy)
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus short-term ADT
Number of subjects: 1979
Study: 19466504

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) at 300 mg twice daily by intravenous drip infusion
Number of subjects: 104

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS) at 500 mg twice daily by intravenous drip infusion
Number of subjects: 104
Study: 16912265

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 9691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9691
Study: 16225723

Group type: EXPERIMENTAL
Intervention: Prostate anaesthetic block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 90
Study: 12450637

Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10548960

Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Number of subjects: 0
Study: 8703665

Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 10
Study: 2274199

Group type: EXPERIMENTAL
Intervention: Propofol + Ketamina
Number of subjects: 43
Study: 343993

Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide applied once daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.05% betamethasone dipropionate cream applied twice daily
Number of subjects: 53
Study: 30433893

Group type: EXPERIMENTAL
Intervention: Vacuum drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual drainage
Number of subjects: 100
Study: 28633582

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD) in dim light (10 lux)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nutritionally balanced control mixture in dim light (10 lux)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD) in bright light (3000 lux)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nutritionally balanced control mixture in bright light (3000 lux)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Light × mixture interaction for reaction time to fear
Number of subjects: 32
Study: 26538383

Group type: EXPERIMENTAL
Intervention: Not the Ice Cream Van (NTICV)
Number of subjects: 20975

Group type: EXPERIMENTAL
Intervention: Goddess Demetra (GD)
Number of subjects: 20975

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20975
Study: 23706899

Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19941014

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 30
Study: 19191743

Group type: EXPERIMENTAL
Intervention: TSH levels (0.3-10.0 mIU/L)
Number of subjects: 489
Study: 17045366

Group type: EXPERIMENTAL
Intervention: dTap
Number of subjects: 593

Group type: COMPARATOR
Intervention: DTaP-IPV
Number of subjects: 593
Study: 15492567

Group type: EXPERIMENTAL
Intervention: Double-lumen gastrojejunostomy tube (GJT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Routine care of the operating surgeon (Control)
Number of subjects: 36
Study: 11550739

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 75
Study: 9586798

Group type: EXPERIMENTAL
Intervention: Older individuals (ARMD, diabetes, and controls)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Diabetic cases
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: ARMD cases
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Older groups
Number of subjects: 119
Study: 8109774

Group type: EXPERIMENTAL
Intervention: Naloxone 1, 2, 4, and 8 micrograms/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nalmefene 1, 2, 4, and 8 micrograms/kg
Number of subjects: 16
Study: 3134343

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 30520980

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffolds (BRS)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 262
Study: 28437263

Group type: EXPERIMENTAL
Intervention: CHO group received oral CHO (400 ml) the prior evening and 2 to 3 hours before surgery.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group was fasted from food and water according to standard protocol.
Number of subjects: 57
Study: 25675222

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel injection
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sterile water injection
Number of subjects: 17
Study: 22678947

Group type: EXPERIMENTAL
Intervention: Memory Support System (MSS) with training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Memory Support System (MSS) without training (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Care partners of MSS trained individuals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Care partners of control group
Number of subjects: 40
Study: 21212377

Group type: EXPERIMENTAL
Intervention: Body-worn accelerometers (activPAL)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Body-worn accelerometers (activPAL) on nonaffected leg
Number of subjects: 46
Study: 19224088

Group type: EXPERIMENTAL
Intervention: Desflurane (6 percent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enflurane (1.2 percent)
Number of subjects: 40
Study: 16828500

Group type: EXPERIMENTAL
Intervention: 0.3-mg pegaptanib continued for 48 weeks (8 injections)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Usual care or discontinuation of pegaptanib
Number of subjects: 1190
Study: 15342284

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 10959738

Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Number of subjects: 356
Study: 9603290

Group type: EXPERIMENTAL
Intervention: 0.25% nipradilol (N = 9) twice daily for 15 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.01% bunazosin (N = 10) twice daily for 20 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2.0% carteolol (N = 6)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.5% betaxolol (N = 10)
Number of subjects: 25
Study: 8256008

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (TNG) - 2 cm of NTG gel administered once a day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparinoid substances - applied three times a day
Number of subjects: 100
Study: 3899248

Group type: EXPERIMENTAL
Intervention: Single phenol injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multiple phenol injection
Number of subjects: 120
Study: 31888708

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral-physical therapy (CBPT) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 29384722

Group type: EXPERIMENTAL
Intervention: ADT in combination with docetaxel 75 mg/m2 for up to six cycles
Number of subjects: 790

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy for high-volume disease (n = 513)
Number of subjects: 790

Group type: COMPARATOR
Intervention: ADT alone for high-volume disease
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy for low-volume disease (n = 277)
Number of subjects: 790

Group type: COMPARATOR
Intervention: ADT alone for low-volume disease
Number of subjects: 790
Study: 27105868

Group type: EXPERIMENTAL
Intervention: 75 mg resveratrol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 150 mg resveratrol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg resveratrol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24556754

Group type: EXPERIMENTAL
Intervention: Complementary feeding before breast-feeding (sequence A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Complementary feeding after breast-feeding (sequence B)
Number of subjects: 25
Study: 23016710

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 140
Study: 20409432

Group type: EXPERIMENTAL
Intervention: Motivational interviewing with standard screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing with proactive screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (brief advice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (overall)
Number of subjects: 0
Study: 18785409

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF hydrogel (100 microg/10 g/100 cm2/d)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 15687007

Group type: EXPERIMENTAL
Intervention: Emotional story version
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral story version
Number of subjects: 0
Study: 12204985

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octylcyanoacrylate, Dermabond)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adhesive strips (Steristrips)
Number of subjects: 60
Study: 11793153

Group type: EXPERIMENTAL
Intervention: Active physiotherapy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Muscle reconditioning on training devices
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low-impact aerobics
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 148
Study: 9625104

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1200 mg elemental Ca/d)
Number of subjects: 60